Cargando…

Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment

SIMPLE SUMMARY: In the field of non-small cell lung cancer (NSCLC), there have been significant advancements in genomic data and bioinformatics tools, which have improved early diagnosis, treatment, and follow-up using biomarkers. Biomarkers provide measurable indicators of disease characteristics a...

Descripción completa

Detalles Bibliográficos
Autores principales: Restrepo, Juan Carlos, Dueñas, Diana, Corredor, Zuray, Liscano, Yamil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340640/
https://www.ncbi.nlm.nih.gov/pubmed/37444584
http://dx.doi.org/10.3390/cancers15133474
_version_ 1785072127705088000
author Restrepo, Juan Carlos
Dueñas, Diana
Corredor, Zuray
Liscano, Yamil
author_facet Restrepo, Juan Carlos
Dueñas, Diana
Corredor, Zuray
Liscano, Yamil
author_sort Restrepo, Juan Carlos
collection PubMed
description SIMPLE SUMMARY: In the field of non-small cell lung cancer (NSCLC), there have been significant advancements in genomic data and bioinformatics tools, which have improved early diagnosis, treatment, and follow-up using biomarkers. Biomarkers provide measurable indicators of disease characteristics and help tailor treatment strategies in precision medicine. The integration of big data and artificial intelligence (AI) further enhances personalized medicine through advanced biomarker analysis. However, challenges exist in terms of limited evidence on the impact of new biomarkers on mortality and treatment efficacy, as well as data analysis and the adoption of precision medicine in clinical practice. Despite these obstacles, the integration of biomarkers into precision medicine has shown promise in improving patient outcomes in NSCLC. Continued research and advancements in biomarker discovery, utilization, and evidence generation are needed to overcome these challenges and further enhance precision medicine’s effectiveness in NSCLC. ABSTRACT: Non-small cell lung cancer (NSCLC) is a significant public health concern with high mortality rates. Recent advancements in genomic data, bioinformatics tools, and the utilization of biomarkers have improved the possibilities for early diagnosis, effective treatment, and follow-up in NSCLC. Biomarkers play a crucial role in precision medicine by providing measurable indicators of disease characteristics, enabling tailored treatment strategies. The integration of big data and artificial intelligence (AI) further enhances the potential for personalized medicine through advanced biomarker analysis. However, challenges remain in the impact of new biomarkers on mortality and treatment efficacy due to limited evidence. Data analysis, interpretation, and the adoption of precision medicine approaches in clinical practice pose additional challenges and emphasize the integration of biomarkers with advanced technologies such as genomic data analysis and artificial intelligence (AI), which enhance the potential of precision medicine in NSCLC. Despite these obstacles, the integration of biomarkers into precision medicine has shown promising results in NSCLC, improving patient outcomes and enabling targeted therapies. Continued research and advancements in biomarker discovery, utilization, and evidence generation are necessary to overcome these challenges and further enhance the efficacy of precision medicine. Addressing these obstacles will contribute to the continued improvement of patient outcomes in non-small cell lung cancer.
format Online
Article
Text
id pubmed-10340640
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103406402023-07-14 Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment Restrepo, Juan Carlos Dueñas, Diana Corredor, Zuray Liscano, Yamil Cancers (Basel) Review SIMPLE SUMMARY: In the field of non-small cell lung cancer (NSCLC), there have been significant advancements in genomic data and bioinformatics tools, which have improved early diagnosis, treatment, and follow-up using biomarkers. Biomarkers provide measurable indicators of disease characteristics and help tailor treatment strategies in precision medicine. The integration of big data and artificial intelligence (AI) further enhances personalized medicine through advanced biomarker analysis. However, challenges exist in terms of limited evidence on the impact of new biomarkers on mortality and treatment efficacy, as well as data analysis and the adoption of precision medicine in clinical practice. Despite these obstacles, the integration of biomarkers into precision medicine has shown promise in improving patient outcomes in NSCLC. Continued research and advancements in biomarker discovery, utilization, and evidence generation are needed to overcome these challenges and further enhance precision medicine’s effectiveness in NSCLC. ABSTRACT: Non-small cell lung cancer (NSCLC) is a significant public health concern with high mortality rates. Recent advancements in genomic data, bioinformatics tools, and the utilization of biomarkers have improved the possibilities for early diagnosis, effective treatment, and follow-up in NSCLC. Biomarkers play a crucial role in precision medicine by providing measurable indicators of disease characteristics, enabling tailored treatment strategies. The integration of big data and artificial intelligence (AI) further enhances the potential for personalized medicine through advanced biomarker analysis. However, challenges remain in the impact of new biomarkers on mortality and treatment efficacy due to limited evidence. Data analysis, interpretation, and the adoption of precision medicine approaches in clinical practice pose additional challenges and emphasize the integration of biomarkers with advanced technologies such as genomic data analysis and artificial intelligence (AI), which enhance the potential of precision medicine in NSCLC. Despite these obstacles, the integration of biomarkers into precision medicine has shown promising results in NSCLC, improving patient outcomes and enabling targeted therapies. Continued research and advancements in biomarker discovery, utilization, and evidence generation are necessary to overcome these challenges and further enhance the efficacy of precision medicine. Addressing these obstacles will contribute to the continued improvement of patient outcomes in non-small cell lung cancer. MDPI 2023-07-03 /pmc/articles/PMC10340640/ /pubmed/37444584 http://dx.doi.org/10.3390/cancers15133474 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Restrepo, Juan Carlos
Dueñas, Diana
Corredor, Zuray
Liscano, Yamil
Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment
title Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment
title_full Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment
title_fullStr Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment
title_full_unstemmed Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment
title_short Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment
title_sort advances in genomic data and biomarkers: revolutionizing nsclc diagnosis and treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340640/
https://www.ncbi.nlm.nih.gov/pubmed/37444584
http://dx.doi.org/10.3390/cancers15133474
work_keys_str_mv AT restrepojuancarlos advancesingenomicdataandbiomarkersrevolutionizingnsclcdiagnosisandtreatment
AT duenasdiana advancesingenomicdataandbiomarkersrevolutionizingnsclcdiagnosisandtreatment
AT corredorzuray advancesingenomicdataandbiomarkersrevolutionizingnsclcdiagnosisandtreatment
AT liscanoyamil advancesingenomicdataandbiomarkersrevolutionizingnsclcdiagnosisandtreatment